Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4563203
Max Phase: Preclinical
Molecular Formula: C72H108N20O18S2
Molecular Weight: 1605.91
Molecule Type: Unknown
Associated Items:
ID: ALA4563203
Max Phase: Preclinical
Molecular Formula: C72H108N20O18S2
Molecular Weight: 1605.91
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@@H]1NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2
Standard InChI: InChI=1S/C72H108N20O18S2/c73-27-7-4-16-45-61(100)87-51(38-93)64(103)83-47(18-6-9-29-75)69(108)92-33-13-22-56(92)71(110)91-32-12-21-55(91)67(106)82-46(17-5-8-28-74)62(101)89-53-40-112-111-39-52(65(104)84-48(63(102)81-45)34-42-23-25-43(94)26-24-42)88-60(99)44(19-10-30-78-72(76)77)80-57(95)37-79-59(98)49(36-58(96)97)85-68(107)54-20-11-31-90(54)70(109)50(86-66(53)105)35-41-14-2-1-3-15-41/h1-3,14-15,23-26,44-56,93-94H,4-13,16-22,27-40,73-75H2,(H,79,98)(H,80,95)(H,81,102)(H,82,106)(H,83,103)(H,84,104)(H,85,107)(H,86,105)(H,87,100)(H,88,99)(H,89,101)(H,96,97)(H4,76,77,78)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-/m0/s1
Standard InChI Key: LYXHXGYOULPEHQ-HBKJHRGCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1605.91 | Molecular Weight (Monoisotopic): 1604.7592 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Swedberg JE, Wu G, Mahatmanto T, Durek T, Caradoc-Davies TT, Whisstock JC, Law RHP, Craik DJ.. (2019) Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma., 62 (2): [PMID:30520638] [10.1021/acs.jmedchem.8b01139] |
Source(1):